Cancer Res Treat.  2023 Jan;55(1):196-218. 10.4143/crt.2022.080.

Changes in Gut Microbiome upon Orchiectomy and Testosterone Administration in AOM/DSS-Induced Colon Cancer Mouse Model

• Song CH
• Kim N
• Nam RH
• Choi SI
• Jang JY
• Lee HN

• KMID: 2538005
• DOI: http://doi.org/10.4143/crt.2022.080

Abstract

Purpose
Sex hormones are known to affect the gut microbiota. Previously, we reported that endogenous and exogenous testosterone are associated with colorectal cancer (CRC) development and submucosal invasion. In the present study, we investigated whether the gut microbiota is affected by orchiectomy (ORX) and testosterone propionate (TP) administration using an azoxymethane/dextran sulfate sodium (AOM/DSS)-induced CRC mouse model.
Materials and Methods
Gut microbiota was evaluated by means of 16S rRNA gene sequencing of stool DNA extracted from feces that were obtained at 13 weeks after AOM injection (from 22-week-old animals) and stored in a gas-generating pouch.
Results
The increase in microbial diversity (Chao1 and Phylogenetic Diversity index) and Firmicutes/Bacteroidetes (F/B) ratio upon AOM/DSS treatment in ORX mice was significantly decreased by TP supplementation. The ratio of commensal bacteria to opportunistic pathogens was lower in the TP-administered females and ORX mice than in the AOM/DSS group. Opportunistic pathogens (Mucispirillum schaedleri or Akkermansia muciniphila) were identified only in the TP group. In addition, microbial diversity and F/B ratio were higher in male controls than in female and ORX controls. Flintibacter butyricus, Ruminococcus bromii, and Romboutsia timonensis showed similar changes in the male control group as those in the female and ORX controls.
Conclusion
In conclusion, testosterone determines the dysbiosis of gut microbiota, which suggests that it plays a role in the sex-related differences in colorectal carcinogenesis.

Keyword

Colitis-associated neoplasms; AOM/DSS mouse model; Orchiectomy; Testosterone; Gastrointestinal microbiome

Figure

• 

  Fig. 1 Study design to evaluate the effect of testosterone on gut microbiota composition during colon tumorigenesis. (A) Study design. Female, male, and orchiectomized mice were treated with AOM/DSS to induce colitis-associated CRC. One week after orchiectomy, all mice were enrolled in the AOM/DSS protocol. The mice were injected with AOM (10 mg/kg bodyweight) on day 0. One week after AOM injection, DSS (2% w/v) was provided in the drinking water for 1 week, followed by normal drinking water. TP was administered by intramuscular (i.m) injection twice a week from the day of surgery to the end of the experiment. Fecal collection and mouse sacrifice were performed at week 13 (22-weeks age) after AOM injection. (B) Data analysis scheme. In comparision group 1, the effects of AOM/DSS-induced CRC and TP addition in AOM/DSS group on the gut microbial composition was examined. In comparision group 2, the effects of male sex hormone on the gut microbial composition was examined. (C–E) Alpha diversity of gut microbiota. Next-generation sequencing was performed with 16S rRNA gene from mouse stool DNA. Observed OTU count (C), Chao1 as a species richness estimator (D), Phylogenetic Diversity as a phylogenetic richness estimator (E) of the intetinal microbiota in female, male, and ORX mice. Data are expressed as the mean±SEM. Whiskers show the minimum and maximum values. Mann-Whitney U test for comparison difference between independent two groups was performed. AOM, azoxymethane; CON, control; CRC, colorectal cancer; DSS, dextran sulfate sodium salt; ORX, orchiectomized; OTU, operational taxonomic unit; SEM, standard error of the mean; TP, testosterone propionate. *p < 0.05 for “CON vs. AOM/DSS” or “AOM/DSS vs. AOM/DSS+TP” in female, male, and ORX groups, †p < 0.05 for “Female vs. Male”, ‡p < 0.05 for “Male vs. ORX”, §p < 0.05 for “Female vs. ORX” in CON, AOM/DSS, and AOM/DSS+TP subgroups.

• 

  Fig. 2 Sample clustering by UniFrac-based PCoA at the species level. (A–F) Clustering to see the difference between control, AOM/DSS, and AOM/DSS+TP in female (A, D), male (B, E), ORX (C, F) group samples by PCoA 2D (A–C) and 3D (D–F) plot. (G–L) Clustering to see the difference between female, male, and ORX in control (G, J), AOM/DSS (H, K), and AOM/DSS+TP (I, L) subgroup samples by PCoA 2D (G–I) and 3D (J–L) plot. Group 1 and group 2 samples were clustered using the Generalized UniFrac method at the species level. Significance for similarity of bacterial population structure was analyzed by PERMANOVA. The clustering of each group is marked with a different color: Female control, filled red ellipse; Female AOM/DSS, filled pink ellipse; Female AOM/DSS+TP, blanked red ellipse; Male control, filled blue ellipse; Male AOM/DSS, filled skyblue ellipse; Male AOM/DSS+TP, blanked blue ellipse; ORX control, filled green ellipse; ORX AOM/DSS, filled light green ellipse; ORX AOM/DSS+TP, blanked green ellipse. AOM, azoxymethane; CON, control; DSS, dextran sulfate sodium salt; ORX, orchiectomized; PCoA, principal coordinates analysis; PERMANOMA, permutational multivariate analysis of variance; TP, testosterone propionate.

• 

  Fig. 3 Gut microbiota compositions at the Phylum and Family levels. (A–L) The microbiota compostion of stool conetnts from group 1 for “AOM/DSS and TP addition” criteria (A–C, G–I) and group 2 for “sex and ORX” criteria (D–F, J–L) at the Phylum (A–F) and Family (G–L) levels. Mann-Whitney U test for comparison difference between independent two groups was performed. †p < 0.05, female vs. male, ‡p < 0.05, male vs. ORX, §p < 0.05, female vs. ORX in CON, AOM/DSS, and AOM/DSS+TP mice within group 2. a)p < 0.05, CON vs. AOM/DSS, b)p < 0.05, AOM/DSS vs. AOM/DSS+TP in female, male, and ORX mice within group 1. (M–O) Firmicutes/Bacteroidetes ratio (M) calculated by dividing the abundance of Firmicutes (N) with that of Bacteroidetes (O) in female, male, and ORX mice. Data are expressed as the mean±SEM. Whiskers show the minimum and maximum values. The p-values were calculated from the Mann-Whitney U test for comparison difference between independent two groups. *p < 0.05 for “CON vs. AOM/DSS” or “AOM/DSS vs. AOM/DSS+TP” in female, male, and ORX groups, †p < 0.05 for “Female vs. Male”, ‡p < 0.05 for “Male vs. ORX”, §p < 0.05 for “Female vs. ORX” in CON, AOM/DSS, and AOM/DSS+TP subgroups. AOM, azoxymethane; CON, control; DSS, dextran sulfate sodium salt; ORX, orchiectomized; SEM, standard error of the mean; TP, testosterone propionate.

• 

  Fig. 4 Changes in the abundance ratio of the gut microbiome by AOM/DSS and TP addition: LEfSe analysis. (A–F) Bar plots of the LEfSe results, which were obtained based on the following criteria: (1) alpha value of the factorial Kruskal-Wallis H test between assigned taxa < 0.05; (2) the alpha value for the pairwise Wilcoxon test among the taxonomic members < 0.05; (3) threshold of the logarithmic LDA score for discriminative features < 2.0; and (4) a multi-class analysis set as all-against-all; (5) identifying and classifying the bacterial characteristics based on previous reports as “commensal bacteria,” “opportunistic pathogens,” and “not characterized”; (6) removal of non-overlapping bacteria from the “not characterized” microbiome; and (7) in the LEfSe plot, all commensal bacteria and opportunistic pathogens, and top ten “not characterized” bacteria were included. The color bars show the LDA scores of species that enriched in indicated conditions; (A) filled red bar (female control), (A, B) hatched blue bar (AOM/DSS-treated female), (B) blanked blue bar (AOM/DSS+TP-treated female), (C) filled red bar (male control), (C, D) hatched red bar (AOM/DSS-treated male), (D) blanked red bar (AOM/DSS+TP-treated male). (E) filled green bar (ORX control), (E, F) hatched green bar (AOM/DSS-treated ORX mice), (F) blanked green bar (AOM/DSS+TP-treated ORX mice). The color on the species name indicates the characteristics of each species: yellow for commensal bacteria, orange for opportunistic pathogens, and green for not characterized bacteria. Asterisks indicate the butyrate-producing bacteria. The p- and q-values were determined using the non-parametric factorial Kruskal-Wallis H test. (G) The ratio of commensal bacteria to opportunistic pathogens based on the LEfSe results in each comparison group. AOM, azoxymethane; DSS, dextran sulfate sodium salt; F, female; LDA, linear discriminant analysis; LEfSe, linear discriminant analysis effect size; M, male; NC, not calculated; ORX, orchiectomized; TP, testosterone propionate.

• 

  Fig. 5 Changes in the abundance ratio of the gut microbiome by sex and ORX: LEfSe analysis. (A–F) Bar plots of the LEfSe results, which were generated based on the criteria mentioned in the legend of Fig. 4. The color bars show the LDA scores of species that enriched in indicated conditions: (A) filled red bar (female control), (A, B) filled blue bar (male control), (B) filled green bar (ORX control), (C) hatched red bar (AOM/DSS-treated female), (C, D) hatched blue bar (AOM/DSS-treated male), (D) hatched green bar (AOM/DSS-treated ORX mice). (E) blanked red bar (AOM/DSS+TP-treated female), (E, F) blanked blue bar (AOM/DSS+TP-treated male), (F) blanked green bar (AOM/DSS+TP-treated ORX mice). The color on the species name indicates the characteristics of each species: yellow for commensal bacteria, orange for opportunistic pathogens, and green for not characterized bacteria. Arstericks indicate the butyrate-producing bacteria. The p- and q-values were determined using the non-parametric factorial Kruskal-Wallis H test. (G) The ratio of commensal bacteria to opportunistic pathogens based on the LEfSe results in each comparison group. AOM, azoxymethane; DSS, dextran sulfate sodium salt; F, female; LDA, linear discriminant analysis; LEfSe, linear discriminant analysis effect size; M, male; NC, not calculated; ORX, orchiectomized; TP, testosterone propionate.

• 

  Fig. 6 Gut microbiome showing changes in “AOM/DSS and TP addition” and “sex and ORX” criteria. (A–C) The abundance ratio of butyrate-producing bacteria among commensal bacteria. (A) Clostridium indolis (Firmicutes: Clostridia: Clostridiales: Lachnospiraceae: Clostridium_g34). (B) Flintibacter butyricus (Firmicutes: Clostridia: Clostridiales: Ruminococcaceae: Pseudoflavonifractor). (C) Kineothrix alysoides (Firmicutes: Clostridia: Clostridiales: Lachnospiraceae: Kineothrix). (D–F) The abundance ratio of commensal bacteria. (D) Parabacteroides goldsteinii (Bacteroidetes: Bacteroidia: Bacteroidales: Porphyromonadaceae: Parabacteroides). (E) Romboutsia timonensis (Firmicutes: Clostridia: Clostridiales: Peptostreptococcaceae: Romboutsia). (F) Ruminococcus bromii (Firmicutes: Clostridia: Clostridiales: Ruminococcaceae: Ruminococcus_g2). (G–J) The abundance ratio of opportunistic pathogens. (G) Bacteroides caccae (Bacteroidetes: Bacteroidia: Bacteroidales: Bacteroidaceae: Bacteroides). (H) Mucispirillum schaedleri (Deferribacteres: Deferribacteres_c: Deferribacterales: Deferribacteraceae: Mucispirillum). (I) Akkermansia muciniphila (Verrucomicrobia: Verrucomicrobiae: Verrucomicrobiales: Akkermansiaceae: Akkermansia). (J) Bacteroides vulgatus (Bacteroidetes: Bacteroidia: Bacteroidales: Bacteroidaceae: Bacteroides). AOM, azoxymethane; CON, control; DSS, dextran sulfate sodium salt; ORX, orchiectomized; SEM, standard error of the mean; TP, testosterone propionate. Data are expressed as the mean±SEM. Whiskers show the minimum and maximum values. The p-values were calculated from the Mann-Whitney U test for comparison difference between independent two groups. *p < 0.05 for “CON vs. AOM/DSS” or “AOM/DSS vs. AOM/DSS+TP” in female, male, and ORX groups, †p < 0.05 for “Female vs. Male”, ‡p < 0.05 for “Male vs. ORX”, §p < 0.05 for “Female vs. ORX” in CON, AOM/DSS, and AOM/DSS+TP subgroups.

Reference

References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021; 71:7–33.

2. McCashland TM, Brand R, Lyden E, de Garmo P, Project CR. Gender differences in colorectal polyps and tumors. Am J Gastroenterol. 2001; 96:882–6.

3. Kim SE, Paik HY, Yoon H, Lee JE, Kim N, Sung MK. Sex- and gender-specific disparities in colorectal cancer risk. World J Gastroenterol. 2015; 21:5167–75.

4. Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev. 2013; 22:1931–43.

5. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004; 350:991–1004.

6. Song M, Hu FB, Spiegelman D, Chan AT, Wu K, Ogino S, et al. Adulthood weight change and risk of colorectal cancer in the nurses’ health study and health professionals follow-up study. Cancer Prev Res (Phila). 2015; 8:620–7.

7. Kim YS, Unno T, Kim BY, Park MS. Sex differences in gut microbiota. World J Mens Health. 2020; 38:48–60.

8. Baker JM, Al-Nakkash L, Herbst-Kralovetz MM. Estrogen-gut microbiome axis: physiological and clinical implications. Maturitas. 2017; 103:45–53.

9. Org E, Mehrabian M, Parks BW, Shipkova P, Liu X, Drake TA, et al. Sex differences and hormonal effects on gut microbiota composition in mice. Gut Microbes. 2016; 7:313–22.

10. Cox-York KA, Sheflin AM, Foster MT, Gentile CL, Kahl A, Koch LG, et al. Ovariectomy results in differential shifts in gut microbiota in low versus high aerobic capacity rats. Physiol Rep. 2015; 3:e12488.

11. Song CH, Kim N, Nam RH, Choi SI, Lee HN, Surh YJ. 17beta-Estradiol supplementation changes gut microbiota diversity in intact and colorectal cancer-induced ICR male mice. Sci Rep. 2020; 10:12283.

12. Wang CZ, Huang WH, Zhang CF, Wan JY, Wang Y, Yu C, et al. Role of intestinal microbiome in American ginseng-mediated colon cancer prevention in high fat diet-fed AOM/DSS mice [corrected]. Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2018; 20:302–12.

13. Zackular JP, Baxter NT, Iverson KD, Sadler WD, Petrosino JF, Chen GY, et al. The gut microbiome modulates colon tumorigenesis. mBio. 2013; 4:e00692–13.

14. Ibrahim A, Hugerth LW, Hases L, Saxena A, Seifert M, Thomas Q, et al. Colitis-induced colorectal cancer and intestinal epithelial estrogen receptor beta impact gut microbiota diversity. Int J Cancer. 2019; 144:3086–98.

15. Shanahan F. The colonic microbiota in health and disease. Curr Opin Gastroenterol. 2013; 29:49–54.

16. Ternes D, Karta J, Tsenkova M, Wilmes P, Haan S, Letellier E. Microbiome in colorectal cancer: how to get from meta-omics to mechanism? Trends Microbiol. 2020; 28:401–23.

17. Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host Microbe. 2014; 15:317–28.

18. Chen Y, Chen Y, Zhang J, Cao P, Su W, Deng Y, et al. Fusobacterium nucleatum promotes metastasis in colorectal cancer by activating autophagy signaling via the upregulation of CARD3 expression. Theranostics. 2020; 10:323–39.

19. Zhang S, Yang Y, Weng W, Guo B, Cai G, Ma Y, et al. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer. J Exp Clin Cancer Res. 2019; 38:14.

20. Son HJ, Sohn SH, Kim N, Lee HN, Lee SM, Nam RH, et al. Effect of estradiol in an azoxymethane/dextran sulfate sodium-treated mouse model of colorectal cancer: implication for sex difference in colorectal cancer development. Cancer Res Treat. 2019; 51:632–48.

21. Song CH, Kim N, Nam RH, Choi SI, Yu JE, Nho H, et al. Testosterone strongly enhances azoxymethane/dextran sulfate sodium-induced colorectal cancer development in C57BL/6 mice. Am J Cancer Res. 2021; 11:3145–62.

22. Song CH, Kim N, Nam RH, Choi SI, Yu JE, Nho H, et al. Changes in microbial community composition related to sex and colon cancer by Nrf2 knockout. Front Cell Infect Microbiol. 2021; 11:636808.

23. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics (Oxford, England). 2014; 30:2114–20.

24. Masella AP, Bartram AK, Truszkowski JM, Brown DG, Neufeld JD. PANDAseq: paired-end assembler for illumina sequences. BMC Bioinformatics. 2012; 13:31.

25. Eddy SR. Accelerated profile HMM searches. PLoS Comput Biol. 2011; 7:e1002195.

26. Lee B, Moon T, Yoon S, Weissman T. DUDE-Seq: fast, flexible, and robust denoising for targeted amplicon sequencing. PLoS One. 2017; 12:e0181463.

27. Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics (Oxford, England). 2010; 26:2460–1.

28. Yoon SH, Ha SM, Kwon S, Lim J, Kim Y, Seo H, et al. Introducing EzBioCloud: a taxonomically united database of 16S rRNA gene sequences and whole-genome assemblies. Int J Syst Evol Microbiol. 2017; 67:1613–7.

29. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, et al. Metagenomic biomarker discovery and explanation. Genome Biol. 2011; 12:R60.

30. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993; 69:238–49.

31. Park YH, Kim N, Shim YK, Choi YJ, Nam RH, Choi YJ, et al. Adequate dextran sodium sulfate-induced colitis model in mice and effective outcome measurement method. J Cancer Prev. 2015; 20:260–7.

32. Katakura K, Lee J, Rachmilewitz D, Li G, Eckmann L, Raz E. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest. 2005; 115:695–702.

33. Choi YJ, Choi YJ, Kim N, Nam RH, Lee S, Lee HS, et al. Acai berries inhibit colon tumorigenesis in azoxymethane/dextran sulfate sodium-treated mice. Gut Liver. 2017; 11:243–52.

34. Son HJ, Kim N, Song CH, Nam RH, Choi SI, Kim JS, et al. Sex-related alterations of gut microbiota in the C57BL/6 mouse model of inflammatory bowel disease. J Cancer Prev. 2019; 24:173–82.

35. Lazar V, Ditu LM, Pircalabioru GG, Gheorghe I, Curutiu C, Holban AM, et al. Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer. Front Immunol. 2018; 9:1830.

36. Kunc M, Gabrych A, Witkowski JM. Microbiome impact on metabolism and function of sex, thyroid, growth and parathyroid hormones. Acta Biochim Pol. 2016; 63:189–201.

37. Shin JH, Park YH, Sim M, Kim SA, Joung H, Shin DM. Serum level of sex steroid hormone is associated with diversity and profiles of human gut microbiome. Res Microbiol. 2019; 170:192–201.

38. Yurkovetskiy L, Burrows M, Khan AA, Graham L, Volchkov P, Becker L, et al. Gender bias in autoimmunity is influenced by microbiota. Immunity. 2013; 39:400–12.

39. Liu R, Zhang C, Shi Y, Zhang F, Li L, Wang X, et al. Dysbiosis of gut microbiota associated with clinical parameters in polycystic ovary syndrome. Front Microbiol. 2017; 8:324.

40. Arroyo P, Ho BS, Sau L, Kelley ST, Thackray VG. Letrozole treatment of pubertal female mice results in activational effects on reproduction, metabolism and the gut microbiome. PLoS One. 2019; 14:e0223274.

41. Magne F, Gotteland M, Gauthier L, Zazueta A, Pesoa S, Navarrete P, et al. The Firmicutes/Bacteroidetes ratio: a relevant marker of gut dysbiosis in obese patients? Nutrients. 2020; 12:1474.

42. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006; 444:1027–31.

43. Mariat D, Firmesse O, Levenez F, Guimaraes V, Sokol H, Dore J, et al. The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol. 2009; 9:123.

44. Raskov H, Burcharth J, Pommergaard HC. Linking gut microbiota to colorectal cancer. J Cancer. 2017; 8:3378–95.

45. Lucas C, Barnich N, Nguyen HT. Microbiota, inflammation and colorectal cancer. Int J Mol Sci. 2017; 18:1310.

46. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005; 102:11070–5.

47. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature. 2009; 457:480–4.

48. Bervoets L, Van Hoorenbeeck K, Kortleven I, Van Noten C, Hens N, Vael C, et al. Differences in gut microbiota composition between obese and lean children: a cross-sectional study. Gut Pathog. 2013; 5:10.

49. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006; 444:1022–3.

50. Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol. 2015; 11:577–91.

51. Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol. 2006; 40:235–43.

52. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013; 504:446–50.

53. Peng L, Li ZR, Green RS, Holzman IR, Lin J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr. 2009; 139:1619–25.

54. Mikkelsen KH, Frost M, Bahl MI, Licht TR, Jensen US, Rosenberg J, et al. Effect of antibiotics on gut microbiota, gut hormones and glucose metabolism. PLoS One. 2015; 10:e0142352.

55. Wang L, Luo HS, Xia H. Sodium butyrate induces human colon carcinoma HT-29 cell apoptosis through a mitochondrial pathway. J Int Med Res. 2009; 37:803–11.

56. Segain JP, Raingeard de la Bletiere D, Bourreille A, Leray V, Gervois N, Rosales C, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn’s disease. Gut. 2000; 47:397–403.

57. Lin HV, Frassetto A, Kowalik EJ Jr, Nawrocki AR, Lu MM, Kosinski JR, et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS One. 2012; 7:e35240.

58. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut. 2006; 55:205–11.

59. Vemuri R, Sylvia KE, Klein SL, Forster SC, Plebanski M, Eri R, et al. The microgenderome revealed: sex differences in bidirectional interactions between the microbiota, hormones, immunity and disease susceptibility. Semin Immunopathol. 2019; 41:265–75.

60. Zhang H, Wang Z, Li Y, Han J, Cui C, Lu C, et al. Sex-based differences in gut microbiota composition in response to tuna oil and algae oil supplementation in a D-galactose-induced aging mouse model. Front Aging Neurosci. 2018; 10:187.

61. Lagkouvardos I, Pukall R, Abt B, Foesel BU, Meier-Kolthoff JP, Kumar N, et al. The Mouse Intestinal Bacterial Collection (miBC) provides host-specific insight into cultured diversity and functional potential of the gut microbiota. Nat Microbiol. 2016; 1:16131.

62. Just S, Mondot S, Ecker J, Wegner K, Rath E, Gau L, et al. The gut microbiota drives the impact of bile acids and fat source in diet on mouse metabolism. Microbiome. 2018; 6:134.

63. Haas KN, Blanchard JL. Kineothrix alysoides, gen. nov., sp. nov., a saccharolytic butyrate-producer within the family Lachnospiraceae. Int J Syst Evol Microbiol. 2017; 67:402–10.

64. Liddicoat C, Sydnor H, Cando-Dumancela C, Dresken R, Liu J, Gellie NJC, et al. Naturally-diverse airborne environmental microbial exposures modulate the gut microbiome and may provide anxiolytic benefits in mice. Sci Total Environ. 2020; 701:134684.

65. Maekawa M, Maekawa M, Ushida K, Hoshi S, Kashima N, Ajisaka K, et al. Butyrate and propionate production from D-mannitol in the large intestine of pig and rat. Microb Ecol Health Dis. 2005; 17:169–76.

66. Wu TR, Lin CS, Chang CJ, Lin TL, Martel J, Ko YF, et al. Gut commensal Parabacteroides goldsteinii plays a predominant role in the anti-obesity effects of polysaccharides isolated from Hirsutella sinensis. Gut. 2019; 68:248–62.

67. Louis P, Flint HJ. Formation of propionate and butyrate by the human colonic microbiota. Environ Microbiol. 2017; 19:29–41.

68. Derrien M, Vaughan EE, Plugge CM, de Vos WM. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol. 2004; 54:1469–76.

69. Gao X, Zhang M, Xue J, Huang J, Zhuang R, Zhou X, et al. Body mass index differences in the gut microbiota are gender specific. Front Microbiol. 2018; 9:1250.

70. Kaliannan K, Robertson RC, Murphy K, Stanton C, Kang C, Wang B, et al. Estrogen-mediated gut microbiome alterations influence sexual dimorphism in metabolic syndrome in mice. Microbiome. 2018; 6:205.

71. Ganesh BP, Klopfleisch R, Loh G, Blaut M. Commensal Akkermansia muciniphila exacerbates gut inflammation in Salmonella Typhimurium-infected gnotobiotic mice. PLoS One. 2013; 8:e74963.

72. Cekanaviciute E, Yoo BB, Runia TF, Debelius JW, Singh S, Nelson CA, et al. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci U S A. 2017; 114:10713–8.

73. Berer K, Gerdes LA, Cekanaviciute E, Jia X, Xiao L, Xia Z, et al. Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc Natl Acad Sci U S A. 2017; 114:10719–24.

74. McCarthy RE, Pajeau M, Salyers AA. Role of starch as a substrate for Bacteroides vulgatus growing in the human colon. Appl Environ Microbiol. 1988; 54:1911–6.

75. Ruseler-van Embden JG, van der Helm R, van Lieshout LM. Degradation of intestinal glycoproteins by Bacteroides vulgatus. FEMS Microbiol Lett. 1989; 49:37–41.

76. Bloom SM, Bijanki VN, Nava GM, Sun L, Malvin NP, Donermeyer DL, et al. Commensal Bacteroides species induce colitis in host-genotype-specific fashion in a mouse model of inflammatory bowel disease. Cell Host Microbe. 2011; 9:390–403.

77. Shih CT, Yeh YT, Lin CC, Yang LY, Chiang CP. Akkermansia muciniphila is negatively correlated with hemoglobin A1c in refractory diabetes. Microorganisms. 2020; 8:1360.